This page shows the latest Vividion Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Tavros will receive $17.5m in a cash upfront payment from Vividion, according to the deal. ... Tavros Therapeutics has teamed up with biopharma Vividion Therapeutics – a wholly owned and independently operated subsidiary of Bayer AG – in a
smaller $101m collaboration with Vividion Therapeutics that also covers cancer and inflammatory diseases targets.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
No results were found
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...